News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Sequenta, Inc.’s ClonoSIGHT Test Validated In Multiple Myeloma By Data To Be Presented At Annual Meeting Of The American Society of Hematology


12/9/2013 7:23:28 AM

biotech jobs post your resume Help employers find you! Check out all the jobs and post your resume.

Sequenta, Inc. today announced that researchers will present data at the 55th annual meeting of the American Society of Hematology (ASH) demonstrating that Sequenta’s ultra-sensitive method for minimal residual disease (MRD) detection is prognostic for both time to tumor progression (TTP) and overall survival (OS) in patients who have been treated for multiple myeloma (MM).

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES